Vrethem M, Ohman S, von Schenck H, Forsberg P, Olsson J E
Acta Neurol Scand. 1987 May;75(5):328-31. doi: 10.1111/j.1600-0404.1987.tb05454.x.
We compared orosomucoid levels in cerebrospinal fluid (CSF) in patients with aseptic meningitis, multiple sclerosis, ischemic and hemorrhagic stroke, CNS-affecting leukemia/lymphoma, and CNS-tumor with the levels in a reference group not having neurologic diseases. Because of possible blood brain barrier damage, we corrected for orosomucoid derived from serum by using the orosomucoid index, i.e. (CSF/serum orosomucoid)/(CSF/serum albumin). Elevated CSF orosomucoid was found in several diseases. In no case, however, was there any evidence of intrathecal synthesis of the protein. We concluded that CSF orosomucoid determination, when used as the only, measure, is of limited clinical value.
我们比较了无菌性脑膜炎、多发性硬化症、缺血性和出血性中风、影响中枢神经系统的白血病/淋巴瘤以及中枢神经系统肿瘤患者脑脊液（CSF）中的类黏蛋白水平与无神经系统疾病的参照组的水平。由于可能存在血脑屏障损伤，我们通过使用类黏蛋白指数，即（脑脊液/血清类黏蛋白）/（脑脊液/血清白蛋白），对源自血清的类黏蛋白进行了校正。在几种疾病中发现脑脊液类黏蛋白升高。然而，在任何情况下均未发现该蛋白鞘内合成的证据。我们得出结论，脑脊液类黏蛋白测定作为唯一的检测手段时，临床价值有限。
